CSF ACR 2022 - Congress Preview (axSpA)
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>ACR</strong> <strong>2022</strong><br />
<strong>Congress</strong> <strong>Preview</strong><br />
<strong>axSpA</strong><br />
Steering Committee Introduction<br />
Dear Colleagues,<br />
Welcome to my selection of the <strong>ACR</strong> abstracts for <strong>axSpA</strong>.<br />
This year’s <strong>ACR</strong> features a number of insightful presentations on the subject of <strong>axSpA</strong> and the therapeutics used to<br />
treat it. Within these pages you will find 26 abstracts that we at the <strong>CSF</strong> think you will find interesting, within which we<br />
have highlighted 14 that are our must-sees. This includes data which reveals the negative impact of weight and sex<br />
on secukinumab persistence, as well as results highlighting an association between spinal pain and quality of life in<br />
ixekizumab therapy.<br />
On Day 1 we have the deeply insightful Spondyloarthritis Including PsA – Treatment Poster I: AxSpA session where a<br />
number Editors Picks’ reside. This includes three deeply interesting posters detailing novel data on bimekizumab (409,<br />
410 & 411), as well as two discussions on the efficacy of upadacitinib in nr-<strong>axSpA</strong> (414 & 419). Hillary Norton then goes<br />
on to provide us with an insightful post-hoc analysis on phase II & III data for tofacitinib use stratified by BMI.<br />
Day 2 kicks off with more data on the relationship of patient BMI and treatment efficacy with a presentation by Uta Kilz<br />
and their discussion on secukinumab persistence (1040). Jan Brandt-Juergens will also be furnishing us with the latest<br />
data on the impact of secukinumab in uveitis (1043) along with two interesting discussions on the safety and efficacy<br />
of ixekizumab (1009 & 1042). Finally, we recommend a poster presentation by Steering Committee member Xenofon<br />
Baraliakos containing a pooled analysis of two-Phase III studies for guselkumab (1037).<br />
There is a limited number of <strong>axSpA</strong> abstracts on Day 3, but we have highlighted an important late breaking abstract<br />
on the effects of secukinumab vs adalimumab biosimilar on radiographic progression in patients with radiographic axial<br />
spondyloarthritis (L15).<br />
As always thank you for your continued support. We hope you have a fantastic time at <strong>ACR</strong> <strong>2022</strong>.<br />
Kind regards<br />
Professor Atul Deodhar<br />
SPONSORSHIP AND UNRESTRICTED EDUCATIONAL GRANTS FROM<br />
Register for FREE content at www.cytokinesignalling.com<br />
DEVELOPED UNDER<br />
THE AUSPICES OF THE<br />
Follow us at:<br />
Cytokine Signalling Forum
Editor’s Picks<br />
Key Presentations<br />
Saturday, 12 November <strong>2022</strong><br />
13:00–<br />
15:00<br />
0403<br />
0404<br />
0405<br />
0409<br />
0410<br />
0411<br />
0412<br />
0414<br />
POSTER SESSION<br />
SPONDYLOARTHRITIS INCLUDING PSA –<br />
TREATMENT POSTER I: AXSPA<br />
Efficacy and Safety of Ixekizumab in Chinese<br />
Patients with Radiographic Axial Spondyloarthritis:<br />
16-Week Results from a Phase 3 Study<br />
Yu Xue<br />
Site-Specific Responses of Joint and Entheses to<br />
Tofacitinib in Patients with Ankylosing Spondylitis: A<br />
Post Hoc Analysis of a Phase 3 Trial<br />
Raphael Micheroli<br />
Efficacy and Safety of Tofacitinib in Patients with<br />
Ankylosing Spondylitis by Baseline BMI: A Post Hoc<br />
Analysis of Phase 2 and Phase 3 Trials<br />
Hillary Norton<br />
Bimekizumab Improves Key Patient Reported<br />
Symptoms of Axial Spondyloarthritis Including Spinal<br />
Pain and Fatigue: Results from Two Phase 3 Studies<br />
Philip J . Mease<br />
Achieving Increasingly Stringent Clinical Response<br />
Criteria & Lower Levels of Disease Activity Is<br />
Associated with Greater Improvements in Physical<br />
Function & HRQoL in Patients with Active Axial<br />
Spondyloarthritis: 16-Week Results from Two Phase<br />
3 Randomized, Placebo-Controlled Studies<br />
Marina Magrey<br />
Bimekizumab Improves Signs and Symptoms<br />
Including Inflammation in Patients with Active<br />
Ankylosing Spondylitis: 24-Week Efficacy & Safety<br />
from a Phase 3, Multicenter, Randomized, Placebo<br />
Controlled Study<br />
Désirée van der Heijde<br />
Bimekizumab Improves Physical Function and<br />
Health-Related Quality of Life in Patients with Axial<br />
Spondyloarthritis: Results from Two Phase 3 Studies<br />
Maureen Dubreuil<br />
Efficacy and Safety of Upadacitinib in Patients with<br />
Ankylosing Spondylitis with Intolerance to And/<br />
or Lack of Efficacy of Prior Biologic Therapy: A<br />
Subgroup Analysis<br />
Xenofon Baraliakos<br />
0416<br />
0419<br />
0421<br />
0422<br />
0425<br />
0426<br />
0427<br />
0429<br />
Efficacy and Safety of Biological DMARDs: A<br />
Systematic Literature Review Informing the <strong>2022</strong><br />
Update of the ASAS-EULAR Recommendations for<br />
the Management of Axial Spondyloarthritis<br />
Casper Webers<br />
Efficacy of Upadacitinib in Patients with Non-<br />
Radiographic Axial Spondyloarthritis Stratified by<br />
Objective Signs of Inflammation at Baseline<br />
Walter P Maksymowych<br />
Efficacy and Safety of Tofacitinib in Patients with<br />
Ankylosing Spondylitis by Prior bDMARD Treatment:<br />
Analysis of a Phase 3 Trial<br />
Atul Deodhar<br />
Efficacy and Safety of Secukinumab in the<br />
Treatment of Axial Spondyloarthritis: Real-Life Data<br />
from TURKBIO Cohor<br />
Semih Gulle<br />
Upadacitinib Pharmacokinetics and Exposure-<br />
Response Relationships for Efficacy and Safety in<br />
Axial Spondyloarthritis – Analyses of the Phase 3<br />
Studies (SELECT-AXIS 1 and 2)<br />
Sumit Bhatnagar<br />
The Relative Efficacy of Biologic and Targeted<br />
Synthetic DMARDs in Ankylosing Spondylitis: A<br />
Network Meta-Analysis<br />
Jesus Diaz & Adela Castro<br />
Recapture Rates with Ixekizumab After Withdrawal<br />
of Therapy in Patients with Axial Spondyloarthritis:<br />
Results at Week 104 from a Randomized Placebocontrolled<br />
Withdrawal Study<br />
Robert Landewé & Rebecca Bolce<br />
No Change in Serum Levels of Bone Turnover<br />
Markers Corrected for Age and Gender During the<br />
First Year of Secukinumab Treatment in Patients with<br />
Ankylosing Spondylitis<br />
Mark Siderius
Editor’s Picks<br />
17:00–<br />
17:10<br />
0544<br />
ORAL SESSION<br />
ABSTRACTS: SPONDYLOARTHRITIS<br />
INCLUDING PSA – TREATMENT I: AXIAL<br />
SPONDYLOARTHRITIS<br />
Bimekizumab Improves Signs and Symptoms,<br />
Including Inflammation, in Patients with Active<br />
Non-Radiographic Axial Spondyloarthritis: 24-Week<br />
Efficacy & Safety from a Phase 3, Multicenter,<br />
Randomized, Placebo Controlled Study<br />
Atul Deodhar<br />
Sunday, 13 November <strong>2022</strong><br />
09:00–<br />
10:30<br />
1009<br />
1036<br />
1037<br />
1040<br />
1042<br />
1043<br />
1509<br />
POSTER SESSION<br />
SPONDYLOARTHRITIS INCLUDING PSA –<br />
TREATMENT POSTER II: MIXED<br />
Efficacy and Improvement in Patient-Reported<br />
Outcomes at Weeks 16 and 52 in Ixekizumab<br />
Treated Biological Naïve Patients with Radiographic<br />
Axial Spondyloarthritis Achieving Clinically Important<br />
Pain at Night Reduction at Week 16: Results from<br />
COAST-V Trial<br />
Sofia Ramiro<br />
Efficacy and Safety of Tofacitinib in Patients with<br />
Psoriatic Arthritis or Ankylosing Spondylitis by<br />
History of Cigarette Smoking<br />
Alexis Ogdie<br />
Performance of BASDAI vs. ASDAS in Evaluating<br />
Axial Involvement in Patients with PsA Treated<br />
with Guselkumab: Pooled Analysis of Two Phase 3<br />
Studies<br />
Xenofon Baraliakos<br />
Impact of Weight and Sex on Long-term Persistence<br />
to Secukinumab Treatment in Patients with Active<br />
Psoriatic Arthritis or Ankylosing Spondylitis<br />
Long-term Safety of Ixekizumab in Adult Patients<br />
with Psoriasis, Psoriatic Arthritis, and Axial<br />
Spondyloarthritis<br />
Atul Deodhar<br />
Uveitis in Patients with Axial Spondyloarthritis or<br />
Psoriatic Arthritis: Baseline Characteristics and<br />
Incidence Rates During Secukinumab and Placebo<br />
Comparative Phase: A Post Hoc Analysis<br />
Jan Brandt-Juergens<br />
Patient Clusters Identified by Machine Learning<br />
from a Pooled Analysis of the Clinical Development<br />
Program of Secukinumab in Psoriatic Arthritis,<br />
Ankylosing Spondylitis and Psoriatic Arthritis with<br />
Axial Manifestations
Editor’s Picks<br />
Monday, 14 November <strong>2022</strong><br />
13:00–<br />
15:00<br />
L14<br />
L15<br />
POSTER SESSION<br />
LATE-BREAKING ABSTRACT POSTER<br />
Bimekizumab Maintains Improvements in<br />
Efficacy Endpoints and Has a Consistent Safety<br />
Profile Through 52 Weeks in Patients with Non-<br />
Radiographic Axial Spondyloarthritis and Ankylosing<br />
Spondylitis: Results from Two Parallel Phase 3<br />
Studies<br />
Sofia Ramiro<br />
Effect of Secukinumab versus Adalimumab<br />
Biosimilar on Radiographic Progression in Patients<br />
with Radiographic Axial Spondyloarthritis: A<br />
Randomized Phase IIIb Study<br />
Xenofon Baraliakos<br />
Notes<br />
Register for FREE content at www.cytokinesignalling.com<br />
DEVELOPED UNDER<br />
THE AUSPICES OF THE<br />
Follow us at:<br />
Cytokine Signalling Forum
Change language